0.24
+8.16%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Traws Pharma
From its filings with the US Securities and Exchange Commission
Traws Pharma is based in Newtown, Pennsylvania and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker TRAW. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $2.8m and net income of $9.2m. At that date it held total assets of $10.6m and shareholders' equity of −$629,000.
Traws Pharma, Inc. (“Traws,” “we,” or the “Company”) is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. We are advancing novel investigational antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health. Our product candidates are intended to be safe, with simple dosing regimens. We strive to utilize accelerated clinical trial strategies with a commitment to patients who are especially vulnerable.
On April 1, 2024, the Company (then known as Onconova Therapeutics, Inc.) consummated a merger (the “Merger”) with Trawsfynydd Therapeutics, Inc. (“Trawsfynydd”), a privately-held biotechnology company developing next-generation, best-in-class antivirals for influenza, COVID-19 and other infectious diseases. Prior to the Merger, the focus of our business was the discovery and development of novel products for patients with cancer. After completion of the Merger, the focus of our business expanded to include the development of novel therapies to target critical threats to human health in respiratory viral diseases.
Quoted from its 10-K, filed 15 Apr 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 25 Jul 2013
- Employees
- 16
- Website
- onconova.com ↗
- Head office
- 12 PENNS TRAIL, NEWTOWN, PA, 18940
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Jack StoverIndependent Chairman of the Board, since 2016$226,491
- Dr. Iain DukesChief Executive Officer, Director, since 2024
- Mr. Charles ParkerChief Financial Officer
- Dr. Nikolay SavchukChief Operating Officer, Director, since 2024
- Dr. C. David PauzaChief Scientific Officer, Virology
- Dr. Robert RedfieldChief Medical Officer
- Dr. Werner CautreelsDirector, since 2024$647,582
- Dr. Trafford ClarkeIndependent Director$103,991
- Dr. John LeamanIndependent Director
- Ms. M. Teresa ShoemakerIndependent Director$117,991
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- The company has molecularly targeted agents for cancer.
- It possesses two clinical-stage programs for development.
- Narazaciclib targets specific cellular pathways effectively.
Weaknesses
- The firm employs only sixteen full-time staff members.
- It operates as a clinical-stage entity without revenue.
- The website domain does not match the company name.
Opportunities
- Supporting investigator-initiated studies expands research scope.
- Combining rigosertib with PD-1 inhibitors offers new paths.
- Targeting mutated K-Ras genes addresses unmet needs.
Threats
- Competitors may develop superior oncology therapeutics.
- Clinical trial results could fail to show efficacy.
- Regulatory hurdles might delay product approvals.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.